Affordable Access

Access to the full text

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR -mutant glioblastoma

Authors
  • Makhlin, Igor1
  • Salinas, Ryan D2
  • Zhang, Daniel3
  • Jacob, Fadi4, 5
  • Ming, Gou-li4
  • Song, Hongjun4, 6
  • Saxena, Deeksha7
  • Dorsey, Jay F7
  • Nasrallah, MacLean P6, 8
  • Morrissette, Jennifer JD8, 9
  • Binder, Zev A2, 6
  • O'Rourke, Donald M2, 6
  • Desai, Arati S1, 6
  • Brem, Steven2, 6
  • Bagley, Stephen J1, 6
  • 1 Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
  • 2 Department of Neurosurgery, University of Pennsylvania, Philadelphia, PA 19104, USA
  • 3 Biochemistry & Molecular Biophysics Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
  • 4 Department of Neuroscience & Mahoney Institute for Neurosciences, University of Pennsylvania, Philadelphia, PA 19104, USA
  • 5 The Solomon H Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
  • 6 GBM Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
  • 7 adelphia, PA 19104, USA
  • 8 Department of Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
  • 9 Center for Personalized Diagnostics, Department of Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
Type
Published Article
Journal
CNS Oncology
Publisher
Future Medicine
Publication Date
Nov 15, 2019
Volume
8
Issue
3
Identifiers
DOI: 10.2217/cns-2019-0014
PMID: 31769726
PMCID: PMC6880297
Source
PubMed Central
Keywords
License
Green

Abstract

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and carries a dismal prognosis. The EGFR gene is among the most commonly deranged genes in GBM and thus an important therapeutic target. We report the case of a young female with heavily pretreated EGFR -mutated GBM, for whom we initiated osimertinib, an oral, third-generation tyrosine kinase inhibitor that irreversibly inhibits EGFR and has significant brain penetration. We then review some of the main challenges in targeting EGFR, including lack of central nervous system penetration with most tyrosine kinase inhibitors, molecular heterogeneity of GBM and the need for enhanced specificity for the EGFR mutations relevant in GBM.

Report this publication

Statistics

Seen <100 times